Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared on X about a recent paper published on The Lancet:
” New EBCTCG meta-analysis in The Lancet: For postmenopausal women with ER+ early breast cancer who’ve already completed 5 years of endocrine therapy, 5 more years of aromatase inhibitors cut distant recurrence risk by ~25%.
Absolute benefit is greater in N+ disease, but comes with higher fracture risk.”
Title: Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy
More posts featuring Yüksel Ürün.